VivoSeq
Rare Disease

Muckle-Wells Syndrome

4

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Muckle-Wells syndrome is an early-stage landscape with 4 programs across 2 companies. The most active players are Novartis, Kiniksa Pharmaceuticals (UK), Ltd.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

67/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

2 programs

Phase 3K

Kiniksa Pharmaceuticals (UK), Ltd.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

4programs
Small molecule250%
Monoclonal antibody125%
Protein / enzyme125%

Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Withdrawn1 · 33%

Clinical Trials

Trial Activity

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome
Completed·Novartis logoNovartis·Phase 3·NCT00465985·35 enrolled
Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)
Completed·—·Phase 2·NCT01045772·10 enrolled
A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
Withdrawn·National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 1/2·NCT01211977

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)